{
  "docId": "019de070-2277-75da-968a-7dffc3addc7d",
  "docSlug": "9a22f83671fc7371cae4ff7d98099963",
  "documentTitle": "Fusion Pharmaceuticals | IPO Presentation Deck | 49 slides",
  "authorId": "fusion-pharmaceuticals",
  "authorName": "Fusion Pharmaceuticals",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2020-06-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 24,
  "pageCount": 49,
  "prevPage": 23,
  "nextPage": 25,
  "slideType": "timeline",
  "function": "plan_implementation",
  "density": "balanced",
  "nDataPoints": 2,
  "notes": "Includes specific DLT observation period assumptions and context regarding COVID-19 trial interruptions.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de070-2277-75da-968a-7dffc3addc7d/24",
  "deckHref": "/decks/019de070-2277-75da-968a-7dffc3addc7d",
  "deckJsonHref": "/decks/019de070-2277-75da-968a-7dffc3addc7d.json",
  "deckAnchorHref": "/decks/019de070-2277-75da-968a-7dffc3addc7d#slide-24",
  "components": [
    {
      "bbox": {
        "h": 0.4,
        "w": 0.9,
        "x": 0.05,
        "y": 0.15
      },
      "kind": "diagram",
      "text": "Phase 1 Single-Dose to Phase 1 Multi-Dose to Phase 2a Study Initiation",
      "attrs": null,
      "subkind": "timeline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "363af9a4-9c7b-4420-b9aa-c42aeee9f9a4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.8,
        "x": 0.05,
        "y": 0.65
      },
      "kind": "list",
      "text": "Phase 1 single-dose portion assumes 56 day DLT observation period; Phase 1 multi-dose portion assumes 42 day DLT observation period; Variability in clinical trial duration attributable to timing of potential DLT observations",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "edc3a416-de05-4dda-b453-4abba86806bc",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.6,
        "x": 0.2,
        "y": 0.9
      },
      "kind": "subtitle",
      "text": "Clinical trial durations reflect # of months post-restart of trial enrollment following interruptions resulting from COVID-19",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7d5257e1-8521-4ce3-82dc-f198a5147052",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.5,
        "x": 0.03,
        "y": 0.03
      },
      "kind": "title",
      "text": "FPI-1434 – Overview of Clinical Trial and Timelines",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d250d94f-f4dc-488e-bb5b-3dc57efcb710",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "timeline",
      "slug": null,
      "matchId": "fd2c5716-912b-4424-a149-8a87bd32d69b",
      "evidence": "Visual progression of clinical trial phases",
      "confidence": 1
    }
  ],
  "arcBeats": [
    {
      "to": 28,
      "from": 19,
      "beatId": "808eda63-f5f8-4631-9599-1a2134d2ac37",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Traction",
      "beatSlug": null,
      "evidence": "The deck presents data and results from Fusion Pharmaceuticals' clinical trials, demonstrating its progress and potential.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    }
  ],
  "loops": [
    {
      "to": 28,
      "from": 23,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "f2bba293-ab4d-41e5-a4d1-dfee987f7956",
      "evidence": "The deck presents data on the limitations of current treatment options and the potential benefits of Fusion Pharmaceuticals' approach.",
      "position": 0,
      "objective": "What are the consequences of not adopting Fusion Pharmaceuticals' targeted therapies?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.7,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}